The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company posted Q2 2026 group revenue of US$247 million, up 21% on the prior year, and reaffirmed its full-year revenue guidance.
What did Telix Pharmaceuticals report?
- Q2 2026 group revenue: US$247 million, up 21% year-over-year and 7% quarter-on-quarter
- Precision Medicine revenue: US$202 million, up 30% year-over-year and 9% quarter-on-quarter
- TMS revenue: US$45 million
- FY 2026 revenue and other income expected to exceed US$1 billion, tracking towards the upper end of guidance (US$950â970 million plus US$40 million Regeneron income)
- R&D expenditure guidance updated to US$230â270 million, reflecting increased investment capacity
- Initial non-refundable payment of US$40 million received from strategic partner Regeneron
What else do investors need to know?
Telix Pharmaceuticals continues to make progress across both its Precision Medicine and Therapeutics businesses. The company achieved a key regulatory milestone for the global Phase 3 trial of TLX591-Tx in prostate cancer, with FDA alignment allowing the study to advance to Part 2 in the US. Enrolment is ongoing in several regions, including Australia and China.
In its Precision Medicine business, Telix is nearing full patient enrolment in the BiPASS Phase 3 study for initial prostate cancer diagnosis, and has completed enrolling for its Phase 3 registrational study in Japan for Illuccix. The company is also progressing new regulatory filings and expanding its manufacturing footprint with new facilities in Melbourne, Brussels, and Yokohama.
Telix finalised a major strategic collaboration with Regeneron to develop radiopharmaceutical therapies, receiving an upfront payment and creating a strong platform for future oncology programs. The company also refinanced existing convertible bonds, boosting its capital flexibility.
What did Telix Pharmaceuticals management say?
Dr. Christian Behrenbruch, Managing Director and Group CEO, said:
We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix’s market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value
What’s next for Telix Pharmaceuticals?
Looking ahead, Telix expects FY 2026 revenue and other income to top US$1 billion, and is allocating additional funds to R&D to support the expansion of key clinical programs. Progress in product development, regulatory filings, and the new Regeneron partnership are expected to underpin further growth.
Management flagged ongoing milestones for pivotal clinical trials in both the Therapeutics and Precision Medicine businesses, as well as continued global geographic expansion. The company’s strengthened capital position will support investment in its late-stage pipeline and manufacturing capability, with a focus on bringing new therapies to market.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have declined 40%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 1% over the same period.
The post Telix Pharmaceuticals: Q2 2026 revenue jumps 21% appeared first on The Motley Fool Australia.
Should you invest $1,000 in Telix Pharmaceuticals right now?
Before you buy Telix Pharmaceuticals shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- HUB24 earnings: Record $18.9bn net inflows lift FUA
- Top 3 ASX healthcare stocks to watch
- Contact Energy June 2026 earnings: Sales rise, renewables progress
- 5 things to watch on the ASX 200 on Tuesday
- Here are the top 10 ASX 200 shares today
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.